Spots Global Cancer Trial Database for pancreatic ductal carcinoma
Every month we try and update this database with for pancreatic ductal carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) | NCT06428409 | Colorectal Canc... Pancreatic Duct... Biliary Tract C... | Sacituzumab tir... Fluorouracil (5... Leucovorin (LV)... | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | NCT05288205 | KRAS P.G12C Non-small Cell ... Colorectal Canc... Pancreatic Duct... | JAB-21822 JAB-3312 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | NCT02715804 | Pancreatic Duct... | Biological: PEG... Placebo nab-Paclitaxel Gemcitabine | 18 Years - | Halozyme Therapeutics | |
| A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | NCT02715804 | Pancreatic Duct... | Biological: PEG... Placebo nab-Paclitaxel Gemcitabine | 18 Years - | Halozyme Therapeutics | |
| A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | NCT02715804 | Pancreatic Duct... | Biological: PEG... Placebo nab-Paclitaxel Gemcitabine | 18 Years - | Halozyme Therapeutics | |
| Recurrence After Whipple's (RAW) Study | NCT04596865 | Pancreatic Canc... Ampullary Cance... Bile Duct Cance... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Pancreatic Duct... Pancreatic Duct... Surgery Survivorship Recurrent Cance... Cancer Recurren... Cancer Recurren... Local Recurrenc... | Pancreaticoduod... | - | University Hospital Plymouth NHS Trust | |
| PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer | NCT01839487 | Metastatic Panc... | PEGPH20 Nab-paclitaxel Gemcitabine Dexamethasone Enoxaparin | 18 Years - | Halozyme Therapeutics | |
| PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer | NCT01839487 | Metastatic Panc... | PEGPH20 Nab-paclitaxel Gemcitabine Dexamethasone Enoxaparin | 18 Years - | Halozyme Therapeutics | |
| Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | NCT05288205 | KRAS P.G12C Non-small Cell ... Colorectal Canc... Pancreatic Duct... | JAB-21822 JAB-3312 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
